Specialty Pharmaceutical Company with a Focus in Pain and Addiction

BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference

November 16, 2018

RALEIGH, N.C., Sept. 10, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm Cukier, Chief Executive Officer, will present at the upcoming Janney Montgomery Scott Healthcare Conference taking place September 17-18, 2018 at the Union League Club in New York, NY.  

Presentation Details:
Date:   Monday, September 17, 2018
Time:   12:25 pm
Webcast:    https://cc.callinfo.com/r/17d0noriu7tz7&eom

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) a leading commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain.  BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain and opioid dependence.  BDSI's headquarters is in Raleigh, North Carolina.  

For more information, please visit or follow us:

Internet:   www.bdsi.com
Facebook:   Facebook.com/BioDeliverySI
Twitter:   @BioDeliverySI

BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) and BELBUCA® (buprenorphine) buccal film (CIII) are marketed in the U.S. by BioDelivery Sciences.  For full prescribing information and important safety information on BDSI products please visit www.bdsi.com where the Company promptly posts press releases, SEC filings and other important information or contact the Company at (800) 469-0261.  For full prescribing and safety information on BELBUCA, please visit www.belbuca.com and for full prescribing and safety information on BUNAVAIL, please visit www.bunavail.com.

© 2018 BioDelivery Sciences International, Inc.  All rights reserved.

 

Contacts
Investors:
Mary ColemanBioDelivery Sciences International, Inc.
919-582-9050
mcoleman@bdsi.comMonique Kosse
Managing Director
LifeSci Advisors
212-915-3820
monique@lifesciadvisors.com

dumb client is dumb.jpg

Source: BioDelivery Sciences International, Inc.